Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 82
Tirzepatide dosing: what the trials used
A trial-by-trial map of the dose escalation schedules used across the SURPASS and SURMOUNT programmes, with what each schedule produced at the primary endpoint.
Tirzepatide history: discovery to approval
Six milestones trace how tirzepatide went from a laboratory dual-agonist hypothesis in 2018 to one of the most-studied prescription medicines in the world.
SURMOUNT-OSA post-hoc: who benefits most
SURMOUNT-OSA post-hoc (Sleep, 2026): more-symptomatic patients saw larger subjective gains; objective AHI and weight changes were consistent across subgroups.
What BPC-157 costs in Denmark
BPC-157 has no marketing authorisation in Denmark: no official price, no pharmacy route, no reimbursement. What the grey-market reality looks like.
BPC-157 Denmark: import rules explained
BPC-157 is unauthorised in Denmark. The 2026 personal import rules explicitly restrict doping substances. What the DKMA says and what customs flags.
Tesamorelin: from discovery to FDA approval
How tesamorelin moved from a lab compound to FDA approval in 2010, and why the European application was withdrawn in 2012.
How Tesamorelin works: the mechanism
Tesamorelin binds GHRH receptors in the pituitary, triggers GH pulses, and raises IGF-1. Plain-English guide to the mechanism.
Tesamorelin side effects and safety data
The FDA label and phase-3 trials list injection site reactions, arthralgia, edema, and a threefold rise in new-onset dysglycemia. Here is what the data show.
What tirzepatide costs in Germany
Cash prices, GKV reimbursement rules, PKV coverage, and the AMNOG process that determines what Mounjaro costs in Germany in 2026.
Tirzepatide Germany: import rules explained
Tirzepatide is EU-authorised as Mounjaro in Germany. What AMG § 73 says about importing it from outside the EU, grey-market risks, and how to get it legally.
Semaglutide around knee replacement surgery
A pilot RCT sets out a 48-week semaglutide protocol around total knee replacement in obese patients. Here is what the paper covers and what remains unanswered.
NITs in MASH: disease-activity vs response
A 2026 letter argues non-invasive liver tests after semaglutide reflect disease activity, not validated response. Here is what that means for MASH trial design.